Tianshui Zhongxing Bio-technology Co.,Ltd. (002772.SZ)
CNY 7.85
(2.61%)
CNY 7.85
(2.61%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.53 Billion CNY | -20.38% |
| 2022 | 3.18 Billion CNY | -3.51% |
| 2021 | 3.3 Billion CNY | 15.81% |
| 2020 | 2.84 Billion CNY | 18.2% |
| 2019 | 2.41 Billion CNY | 63.24% |
| 2018 | 1.47 Billion CNY | 1.38% |
| 2017 | 1.45 Billion CNY | 57.99% |
| 2016 | 922.12 Million CNY | 43.01% |
| 2015 | 644.8 Million CNY | 14.51% |
| 2014 | 563.08 Million CNY | 44.18% |
| 2013 | 390.55 Million CNY | 87.39% |
| 2012 | 208.41 Million CNY | 83.26% |
| 2011 | 113.72 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.73 Billion CNY | -9.5% |
| 2024 Q3 | 2.9 Billion CNY | 6.31% |
| 2024 Q1 | 3.01 Billion CNY | 19.05% |
| 2023 FY | 2.53 Billion CNY | -20.38% |
| 2023 Q3 | 3.38 Billion CNY | -1.19% |
| 2023 Q4 | 2.53 Billion CNY | -25.21% |
| 2023 Q2 | 3.43 Billion CNY | -3.68% |
| 2023 Q1 | 3.56 Billion CNY | 11.85% |
| 2022 Q3 | 3.42 Billion CNY | -2.54% |
| 2022 FY | 3.18 Billion CNY | -3.51% |
| 2022 Q4 | 3.18 Billion CNY | -7.05% |
| 2022 Q2 | 3.51 Billion CNY | 1.19% |
| 2022 Q1 | 3.47 Billion CNY | 5.27% |
| 2021 Q4 | 3.3 Billion CNY | 8.0% |
| 2021 FY | 3.3 Billion CNY | 15.81% |
| 2021 Q1 | 3.1 Billion CNY | 8.87% |
| 2021 Q2 | 2.97 Billion CNY | -3.99% |
| 2021 Q3 | 3.05 Billion CNY | 2.59% |
| 2020 Q4 | 2.84 Billion CNY | 1.64% |
| 2020 Q1 | 2.71 Billion CNY | 12.68% |
| 2020 Q2 | 2.77 Billion CNY | 2.29% |
| 2020 Q3 | 2.8 Billion CNY | 0.9% |
| 2020 FY | 2.84 Billion CNY | 18.2% |
| 2019 FY | 2.41 Billion CNY | 63.24% |
| 2019 Q3 | 2.32 Billion CNY | 14.63% |
| 2019 Q2 | 2.03 Billion CNY | -0.65% |
| 2019 Q4 | 2.41 Billion CNY | 3.57% |
| 2019 Q1 | 2.04 Billion CNY | 38.4% |
| 2018 Q4 | 1.47 Billion CNY | 8.08% |
| 2018 FY | 1.47 Billion CNY | 1.38% |
| 2018 Q3 | 1.36 Billion CNY | -1.01% |
| 2018 Q2 | 1.38 Billion CNY | -2.95% |
| 2018 Q1 | 1.42 Billion CNY | -2.36% |
| 2017 Q4 | 1.45 Billion CNY | 88.89% |
| 2017 Q1 | 759.39 Million CNY | -17.65% |
| 2017 Q2 | 748.74 Million CNY | -1.4% |
| 2017 Q3 | 771.23 Million CNY | 3.0% |
| 2017 FY | 1.45 Billion CNY | 57.99% |
| 2016 Q4 | 922.12 Million CNY | 75.9% |
| 2016 FY | 922.12 Million CNY | 43.01% |
| 2016 Q2 | 750.68 Million CNY | 8.65% |
| 2016 Q3 | 524.22 Million CNY | -30.17% |
| 2016 Q1 | 690.94 Million CNY | 7.16% |
| 2015 Q2 | 558.29 Million CNY | 5.79% |
| 2015 Q4 | 644.8 Million CNY | 37.96% |
| 2015 Q3 | 467.39 Million CNY | -16.28% |
| 2015 Q1 | 527.72 Million CNY | -6.28% |
| 2015 FY | 644.8 Million CNY | 14.51% |
| 2014 Q4 | 563.08 Million CNY | 0.0% |
| 2014 FY | 563.08 Million CNY | 44.18% |
| 2014 Q1 | - CNY | 0.0% |
| 2013 FY | 390.55 Million CNY | 87.39% |
| 2012 FY | 208.41 Million CNY | 83.26% |
| 2011 FY | 113.72 Million CNY | 0.0% |